For years, India's pharmaceutical sector has viewed sustainability as a compliance requirement. ESG investments were considered as a separate track, with little connection to the core capital allocation and financing decisions that drive the business. In 2026, that approach is no longer tenable.
Currently, ESG performance in companies is an essential entry requirement for competitive financing and participating in global export markets. This shift is driven by a mix of market and regulatory pressures. International buyers are demanding detailed supply-chain emissions data. Institutional investors are increasingly factoring ESG considerations into capital allocation strategies. At the same time, lenders are linking loan costs directly to the company’s environmental performance.
ESG as the New Gateway to Competitive Capital
Detailed emissions reports, renewable energy use data, diversity and inclusion metrics, and governance aspects like board independence and ethical compliance have become the initial criteria for investors. Very soon, these will be non-negotiable, often causing capital discussions to halt if credible, audited data is not provided.
Firms with clear ESG strategies might gain priority, obtaining better rates, extended repayment options, and access to investor pools focused on sustainability. On the other hand, companies lacking ESG initiatives may face higher borrowing costs and stricter norms.
Today, more than 80 percent of pharmaceutical executives worldwide classify ESG as a core strategic priority. For Indian companies, this commitment extends well beyond the upcoming budget cycle. Majority of the companies are already planning sustainability investments through 2030 and integrating them into their core operational strategies.
Capital markets favour this forward-looking approach, viewing it as a sign of strong governance, trustworthy reporting, and lower credit risk. An example is Indian pharmaceutical firms proactively aligning with investor-supported ESG frameworks such as S&P Global, MSCI, and Sustainalytics, providing transparent disclosures that boost investor trust and emphasize long-term value generation.
Financing Transformation in Practice
Green bonds and sustainability-linked loans, initially focused mainly on energy and infrastructure, are now supporting a wide array of sustainability projects across the pharma sector. These include solar-powered manufacturing lines, energy-efficient cleanroom climate systems, zero-liquid-discharge facilities, and green-certified buildings. Such projects not only comply with regulatory standards but also helps reduce operating costs overtime.
Loans linked to Sustainability initiatives of a company offer performance-based incentives. Interest rates may vary according to measurable environmental goals, such as reducing emissions, increasing renewable energy use, or enhancing water efficiency.
Government initiatives are strengthening this development. India's sovereign green bonds, coupled with SEBI's sustainable finance framework, are setting a more defined stage and bolstering market infrastructure. This, in turn, lessens the risks for participants and signals a commitment to sustainable growth funding over the long haul. With the market anticipated to evolve further this year, the combination of clearer regulations and increasing lender interest is bringing sustainability goals and capital access into closer alignment. This shift is poised to shape investment choices for a wide range of organizations.
ESG as a Strategic Driver of Market Access
For exporters, neglecting ESG compliance now carries significant consequences. This year, these repercussions will occur more quickly and be more severe. Due to the European Union’s Corporate Sustainability Reporting Directive (CSRD) and strict NHS sustainability rules, companies are required to provide detailed, verifiable data on supply-chain emissions.
These obligations directly influence procurement choices, shape regulatory approvals, and can affect access to vital healthcare contracts, impacting both market entry and long-term prospects for growth.
Carbon border taxes are likely to become a key factor, as failing to meet sustainability targets could reduce profits and restrict access to global markets in the future. Many buyers now look beyond price and product quality – the focus is on how suppliers are managing environmental impact and governance practices before awarding contracts.
With pharmaceutical exports moving beyond $30 billion, continued growth will depend on how well companies adjust to the sustainability expectations of their key global markets.
Repositioning Capital for Resilience
Mounting pressures from both capital markets and export customers are prompting a fundamental shift in how organizations allocate capital. They are now treating environmental spending, like energy infrastructure and green chemistry capabilities, as essential operational infrastructure to safeguard export access, rather than as discretionary expenses.
Financial leaders are building the case on practical grounds. These investments reduce exposure to regulatory and operational risks, lower resource costs, and create tangible advantages when negotiating with both lenders and customers.
Over the months ahead, successful environmental capital proposals will need to demonstrate a direct linkage between investments and business outcomes, whether protecting export access or meeting customer requirements.
Looking Ahead
In the coming years, industry leaders will be assessed on their ability to translate ESG commitments into tangible benefits. Soon, the real test for Indian pharmaceutical companies will be to seamlessly integrate ESG principles from boardroom strategies into day-to-day operations.
Organizations integrating sustainability into their capital planning and operations will enhance their competitiveness and support steady growth. By 2030, India's global reputation in pharmaceuticals will rely not only on the medicines produced but also on the responsibility with which they are manufactured and delivered.
This authored article was first published in the ET Pharma on March 13, 2026
